ProQR Therapeutics N.V. — Investor Relations & Filings

ProQR Therapeutics N.V. is a company focused on the discovery and development of transformative RNA therapies for severe genetic disorders. The company's core is its proprietary Axiomer® RNA editing platform, a novel technology designed to make precise edits to RNA. This platform leverages the body's own natural editing machinery, specifically ADAR (Adenosine Deaminase Acting on RNA) enzymes, to correct genetic mutations at the RNA level. By targeting the root cause of diseases, Axiomer® has the potential to create a new class of medicines for a range of rare and common conditions with high unmet medical needs. ProQR advances its technology through internal development programs and strategic collaborations to bring potential new treatments to patients.